Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study

Journal of NeuroVirology

Volumn 22, Issue 3, 2016, Pages 349-357

  Carvalhal, Adriana ^a,b   Gill, M John ^c   Letendre, Scott L ^d   Rachlis, Anita ^e,f   Bekele, Tsegaye ^g   Raboud, Janet ^a,h   Burchell, Ann ^a,g   Rourke, Sean B ^a,b,i  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g ONTARIO HIV TREATMENT NETWORK   (Canada)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ CIHR Centre for REACH in HIV/AIDS (Research Evidence into Action for Community Health)   (Canada)

Author keywords

Antiretroviral; CPE; HIV; Neuropsychological impairment

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM PENETRATION EFFECTIVENESS SCORE; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; DRUG DISTRIBUTION; DRUG PENETRATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MENTAL PERFORMANCE; NEUROLOGIC DISEASE ASSESSMENT; ONTARIO; PREVALENCE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION; WORKING MEMORY; CD4+ T LYMPHOCYTE; DRUG EFFECTS; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOGENICITY; PERMEABILITY; PHYSIOLOGY; PSYCHOLOGY; TRANSPORT AT THE CELLULAR LEVEL; VIROLOGY;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL TRANSPORT; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; COHORT STUDIES; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; ONTARIO; PERMEABILITY; VIRAL LOAD;

EID: 84947125133     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-015-0404-5     Document Type: Article

References (63)

1. Albert SM, Marder K, Dooneief G, Bell K, Sano M, Todak G, Stern Y (1995) Neuropsychologic impairment in early HIV infection. A risk factor for work disability. Arch Neurol 52(5):525–530
2. Anstey KJ, von Sanden C, Salim A, O’Kearney R (2007) Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 166(4):367–378
3. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789–1799
4. Benedict RHB, Schretlen D, Groninger L, Brandt J (1998) Hopkins Verbal Learning Test–Revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12:43–55
5. Brandt J, Benedict RHB (2001) Hopkins Verbal Learning Test--Revised: Professional Manual. Psychological Assessment Resources, Florida
6. Bryant A, Ellis R, Umlauf A, Gouauz B, Soontornniyomkij V, Letendre S, Achim C, Masliah E, Grant I, Moore D (2015) Antiretroviral therapy reduces neurodegeneration in HIV infection. AIDS 29:323–330
7. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26(3):307–319
8. Carvalhal A, Rourke S, Belmonte-Abreu P, Correa J, Goldani L (2006) Evaluation of neuropsychological performance of HIV-infected patients with minor motor cognitive dysfunction treated with highly active antiretroviral therapy. Infection 34:357–360
9. Chesney MA, Ickovics J, Chambers D, Gifford A, Neidig J, Zwickl B, Wu A, P. C. COMMITTEE and A. W. G. O. T. O. C. O. T. A. A. C. T. GROUP (2000) Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS care 12(3):255–266
10. Childs E, Lyles R, Selnes O, Chen B, Miller E, Cohen B, Becker J, Mellors J, McArthur J (1999) Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 52(3):607–607
11. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, Tamburrini E, Cauda R, De Luca A, Silveri MC (2011) Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 76(16):1403–1409
12. Cysique LA, Waters EK, Brew BJ (2011) Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. (Research article)(Report). BMC Neurology 11:148
13. Durvasula RS, Miller EN, Myers HF, Wyatt GE (2001) Predictors of neuropsychological performance in HIV positive women. J Clin Exp Neuropsychol 23:149–63
14. Ellis RJ, Deutsch R, Heaton RK, Marcotte TD, McCutchan JA, Nelson JA, Abramson I, Thal LJ, Atkinson JH, Wallace MR, Grant I (1997) Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 54(4):416–424
15. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S (2011) CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25(14):1747
16. Gibbie T, Mijch A, Ellen S, Hoy J, Hutchison C, Wright E, Chua P, Judd F (2006) Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up. HIV Med 7(2):112–121
17. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (00392499) 42(9):2672–2713
18. Grant I, Sacktor N, McArthur J (2005) HIV neurocognitive disorders. In: Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S (eds) The neurology of AIDS (2nd edn). Oxford University Press, Oxford, pp 357–73
19. Heaton RK, Kirson D, Velin RA, Grant I, a. t. H. Group (1994) The utility of clinical ratings for detecting early cognitive change in HIV infection. Neuropsychology of HIV infection. I. Grant and A. Martin. Oxford University Press, New York, pp 188–206
20. Heaton RK, Marcotte TD, White DA, Ross D, Meredith K, Taylor MJ, Kaplan R, Grant I (1996) Nature and vocational significance of neuropsychological impairment associated with HIV infection. Clin Neuropsychol 10(1):1–14
21. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, McCutchan JA, Reicks C, Grant I (2004) The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10(3):317–331
22. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology 75(23):2087–2096
23. Hilsabeck R, Perry W, Hassanein T (2002) Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 35(2):440–446
24. Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, Thrasher D, Goetz MB, Stefaniak M (2002) Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 59(12):1944–1950
25. Kalmijn S, van Boxtel MP, Verschuren MW, Jolles J, Launer LJ (2002) Cigarette smoking and alcohol consumption in relation to cognitive performance in middle age. Am J Epidemiol 156(10):936–944
26. Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19(4):137–142
27. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65(1):65–70
28. Letendre S, Ances B, Gibson S, Ellis RJ (2009) Neurologic complications of HIV disease and their treatment. Top HIV Med 15(2):32–39
29. Letendre S, Ellis R, Ances B, McCutchan JA (2010) Neurologic complications of HIV disease and their treatment. Top HIV Med 18(2):45–55
30. Marcotte TD, Deutsch R, McCutchan JA, Moore DJ, Letendre S, Ellis RJ, Wallace MR, Heaton RK, Grant I (2003) Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. Arch Neurol 60(10):1406
31. Marder K, Albert SM, McDermott M (1998) Prospective study of neurocognitive impairment in HIV (DANA cohort): Dementia and mortality outcomes. J Neurovirol 4
32. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23(11):1359–1366
33. Martin EM, Sullivan TS, Reed RA, Fletcher TA, Pitrak DL, Weddington W, Harrow M (2001) Auditory working memory in HIV-1 infection. J Int Neuropsychol Soc 7:20–6
34. Mayeux R, Stern Y, Tang MX, Todak G, Marder K, Sano M, Richards M, Stein Z, Ehrhardt AA, Gorman JM (1993) Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology 43(1):176–182
35. Morgan EE, Woods SP, Weber E, Dawson MS, Carey CL, Moran LM, Grant I (2009) HIV-associated episodic memory impairment: evidence of a possible differential deficit in source memory for complex visual stimuli. J Neuropsychiatry Clin Neurosci 21(2):189–198
36. Mothobi NZ, Brew BJ (2012) Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis 25(1):4–9
37. Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, Pérez-Álvarez N, Moltó J, Gómez G, Clotet B (2008) Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 24(10):1301–1307
38. Norman MA, Moore DJ, Taylor M, Franklin D Jr, Cysique L, Ake C, Lazarretto D, Vaida F, Heaton R ( 2011) Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test–Revised, Brief Visuospatial Memory Test–Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol 33:793–804
39. Petrovsky N, Quednow BB, Ettinger U, Schmechtig A, Mossner R, Collier DA, Kuhn KU, Maier W, Wagner M, Kumari V (2010) Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology 35(7):1429–1439
40. Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1(3):385–401
41. Rigbi A, Kanyas K, Yakir A, Greenbaum L, Pollak Y, Ben-Asher E, Lancet D, Kertzman S, Lerer B (2008) Why do young women smoke? V. Role of direct and interactive effects of nicotinic cholinergic receptor gene variation on neurocognitive function. Genes Brain Behav 7(2):164–172
42. Ritola K, Robertson K, Fiscus SA, Hall C, Swanstrom R (2005) Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol 79(16):10830–10834
43. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (London, England) 21(14):1915–1921
44. Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest DJ (2010) Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 74(16):1260–1266
45. Robertson K, Liner J, Meeker R (2012) Antiretroviral neurotoxicity. J Neurovirol 18(5):388–399
46. Rourke SB, Gardner S, Burchell AN, Raboud J, Rueda S, Bayoumi AM, Loutfy M, Cooper C, Smieja M, Taylor D, DiPede T, Wobeser W, Major C, Waring V, Fisher M, Cairney J, Mittmann N, Salit IE, Crouzat F, Gough K, Ralph E, Sandre R, Kilby D, Rachlis A (2012) Cohort profile: the Ontario HIV Treatment Network Cohort Study (OCS). Int J Epidemiol 42:402–411
47. Ryan E, Morgello S, Isaacs K, Naseer M, Gerits P (2004) Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 62(6):957–962
48. Saunders JB, Aasland OG, Babor TF, Fuente JR, Grant M (1993) Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II. Addiction 88(6):791–804
49. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (London, England) 25(3):357–365
50. Trepanier LL, Rourke SB, Bayoumi AM, Halman MH, Krzyzanowski S, Power C (2005) The impact of neuropsychological impairment and depression on health-related quality of life in HIV-infection. J Clin Exp Neuropsychol 27(1):1–15
51. Trites R (1989) Grooved pegboard test. Lafayette, Ind.: Lafayette Instrument
52. Tulsky DS (2003) Clinical interpretation of the WAIS-III and WMS-III. Academic Press, Amsterdam, Boston
53. Underwood J, Robertson K, Winston A (2015) Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease? AIDS 29:253–261
54. Vassallo M, Durrant J, Biscay V, Lebrum-Frenay C, Dunais B, Laffon M, Harvey-Langton A, Cottalorda J, Ticchioni M, Carsenti H, Pradier C, Dellamonica P (2014) Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? AIDS 28:493–501
55. Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, Power C (2010) Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology 75(13):1150–1158
56. Wagner M, Schulze-Rauschenbach S, Petrovsky N, Brinkmeyer J, von der Goltz C, Grunder G, Spreckelmeyer KN, Wienker T, Diaz-Lacava A, Mobascher A, Dahmen N, Clepce M, Thuerauf N, Kiefer F, de Millas JW, Gallinat J, Winterer G (2013) Neurocognitive impairments in non-deprived smokers—results from a population-based multi-center study on smoking-related behavior. Addict Biol 18(4):752–761
57. Wechsler D (1981) Manual for the Wechsler Adult Intelligence Scale-Revised (WAIS-R). The Psychological Corporation, San Antonio, TX
58. Wechsler D (1997) WAIS-III/WMS-III technical manual. The Psychological Corporation, San Antonio, TX
59. Winterer G, Musso F, Konrad A, Vucurevic G, Stoeter P, Sander T, Gallinat J (2007) Association of attentional network function with exon 5 variations of the CHRNA4 gene. Hum Mol Genet 16(18):2165–2174
60. Winterer G, Mittelstrass K, Giegling I, Lamina C, Fehr C, Brenner H, Breitling LP, Nitz B, Raum E, Muller H, Gallinat J, Gal A, Heim K, Prokisch H, Meitinger T, Hartmann AM, Moller HJ, Gieger C, Wichmann HE, Illig T, Dahmen N, Rujescu D (2010) Risk gene variants for nicotine dependence in the CHRNA5-CHRNA3-CHRNB4 cluster are associated with cognitive performance. Am J Med Genet B Neuropsychiatr Genet 153b(8):1448–1458
61. Woods SP, Iudicello JE, Moran LM, Carey CL, Dawson MS, Grant I (2008) HIV-associated prospective memory impairment increases risk of dependence in everyday functioning. Neuropsychology 22(1):110–117
62. Yakir A, Rigbi A, Kanyas K, Pollak Y, Kahana G, Karni O, Eitan R, Kertzman S, Lerer B ( 2007) Why do young women smoke? III. Attention and impulsivity as neurocognitive predisposing factors. Eur Neuropsychopharmacol 17:339–51
63. Zipursky A, Gogolishvili D, Rueda S, Atkinson M, Brunetta J, Carvalhal A, Collins E, McCombe J, Gill J, Arbess G, Marcotte J, Rourke S (2013) Evaluation of brief screening tools for neurocognitive tools for HAND. AIDS 27(15):2385–2401